LF 08-0299 in the prophylaxis and treatment of chronic rejection in a rat aortic allograft model
Language English Country Switzerland Media print
Document type Journal Article
PubMed
11112075
DOI
10.1007/s001470050404
Knihovny.cz E-resources
- MeSH
- Aorta transplantation MeSH
- Chronic Disease MeSH
- Cyclosporine pharmacology MeSH
- Transplantation, Homologous immunology MeSH
- Immunosuppressive Agents pharmacology MeSH
- Carbamates pharmacology MeSH
- Rats MeSH
- Rats, Inbred BN MeSH
- Rats, Inbred Lew MeSH
- Graft Rejection immunology prevention & control MeSH
- Transplantation, Isogeneic immunology MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Cyclosporine MeSH
- Immunosuppressive Agents MeSH
- Carbamates MeSH
- tresperimus MeSH Browser
Chronic rejection is the major cause of late kidney allograft failure. We evaluated the efficacy of LF 08-299 (LF), an analogue of 15-deoxyspergualin, in a rat aortic allograft model of chronic rejection. BN aortic allografts were transplanted to Lew recipients. LF was administered at a dose of 6 mg/kg and 2.5 mg/kg on days 0-20 and 6 mg/kg on days 60-90. CyA was used at a dose of 5 mg/kg on days 0-20. Untreated isografts and allografts were used as controls. Histological changes and immunohistochemistry were monitored sequentially at 8, 12, 16 and 20 weeks. There were no differences in intimal proliferation between LF-treated allografts and untreated or CyA-treated controls. Only a tendency in adventitial infiltration reduction was seen in LF-treated animals. We found a significantly less pronounced reduction in media diameter in LF-treated animals. We concluded that LF 08-0299 is only able to reverse reduction in media thickness in aortic allografts, but not intimal proliferation in this model of chronic rejection.
References provided by Crossref.org